GlassScriptPhysician profile
Murphy F Townsend
NPI 1790862506
$3,935.16
in general payments reported to CMS, 2019-2025
27 companies · $31.96 in 2025
The $31.96 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $508 · 2020: $320 · 2021: $404 · 2022: $1,201 · 2023: $735 · 2024: $737 · 2025: $31.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,503.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $986.78 | 2022-2024 | Aquabeam Robotic System, Aquabeam System |
| Boston Scientific Corporation | $774.77 | 2019-2025 | Greenlight Xps, Rezum Generator, Lithocatch |
| Teleflex LLC | $497.44 | 2023-2024 | Urolift |
| Srs Medical Systems, INC. | $188.13 | 2021-2022 | |
| Astellas Pharma US INC | $174.61 | 2019-2024 | Xtandi |
| Myovant Sciences INC. | $168.78 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $144.63 | 2019 | |
| Olympus America INC. | $133.66 | 2022 | |
| Karl Storz Endoscopy-America | $99.75 | 2021 | |
| Janssen Biotech, INC. | $98.60 | 2019-2023 | Erleada |
| Neotract INC. | $95.13 | 2019-2020 | |
| Pfizer INC. | $91.81 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $69.32 | 2023-2024 | Orgovyx, Gemtesa |
| Endo Pharmaceuticals INC. | $64.21 | 2020-2023 | Aveed, Xiaflex |
| Bayer Healthcare Pharmaceuticals INC. | $63.19 | 2022-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $54.01 | 2022-2024 | |
| Ambu INC. | $30.96 | 2021 | |
| Merck Sharp & Dohme LLC | $28.62 | 2023 | Welireg, Keytruda, Lynparza |
| Ferring Pharmaceuticals INC. | $22.88 | 2024 | Adstiladrin |
| C. R. Bard, INC. & Subsidiaries | $22.42 | 2022 | |
| Agiliti Surgical, INC. | $21.26 | 2023 | Trinity, Sonablate, Soltive |
| Coloplast Corp | $20.76 | 2024 | |
| Photocure INC | $20.58 | 2021 | |
| Blue Earth Diagnostics | $17.86 | 2019 | |
| Therapeuticsmd, INC. | $17.08 | 2019 | |
| Travere Therapeutics, INC. | $15.26 | 2019-2021 | |
| Abbvie INC. | $12.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murphy Townsend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.